This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NIH State of the Science Panel (2005) National Institutes of Health State of the Science Conference Statement: management of menopause-related symptoms. Ann Int Med 142: 1003–1013
Rossauw JE et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333
Sanchez-Guerrero J et al. (1995) Postmenopausal hormone therapy and the risk of developing systemic lupus erythematosus. Ann Int Med 122: 430–433
Julkunen HA (1991) Oral contraceptives in systemic lupus erythematosus: side effects and influence on the activity of SLE. Scand J Rheumatol 20: 427–433
Arden NK et al. (1994) Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 3: 11–13
Acknowledgements
The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ramsey-Goldman, R. Does hormone replacement therapy affect disease activity in patients with systemic lupus erythematosus?. Nat Rev Rheumatol 1, 72–73 (2005). https://doi.org/10.1038/ncprheum0045
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0045